A major scientific advance in protein modeling developed by Microsoft Research AI for Science, has been published in Science.

SNRI combined with esketamine nasal spray is better at lowering clinical risks of treatment-resistant depression. Credit: pxhere.com ...

Spravato nasal spray, also known as esketamine, can now be used to treat depression in adults with treatment-resistant depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.

Meeting Coverage > Psych Congress Esketamine Also Effective Without Adjunctive Antidepressant — Trial data may expand use, with "opportunity to truly individualize treatment" ...

The present study utilized the spared nerve injury (SNI) to create a mouse model of depression to investigate the impact of esketamine on depressive-like behaviors, on the expression of PSD-95 and ...

For more information on esketamine treatment and to sign up for a free consultation, visit the Active Path Mental Health website. This segment sponsored by Active Path Mental Health.

Data suggest that a low dose of esketamine immediately after childbirth reduces major depressive episodes in women with prenatal depression.

Low-dose esketamine administered post-labor significantly reduced depressive symptoms in women with prenatal depression within 42 days, despite an increase in short-lived neuropsychiatric side ...

A single low dose injection of esketamine given immediately after childbirth reduces major depressive episodes in individuals with depressive symptoms during pregnancy (prenatal depression), finds ...

Esketamine administered intravenously during elective cesarean delivery may significantly reduce depressive symptoms in the early postpartum period, according to study results published in JAMA ...